Novartis' Unbranded Diovan Ads Draw FDA Scrutiny
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has concerns that the unbranded ad, which is connected to a disease awareness program, too heavily references Novartis. The company has its own concerns that unbranded ads may not be effective in the anti-hypertensive market.
You may also be interested in...
Novartis Ends Hypertension DTC Campaign After FDA Objects To Diovan Link
Novartis has discontinued its unbranded direct-to-consumer advertising campaign on hypertension awareness following objections by FDA
Novartis Ends Hypertension DTC Campaign After FDA Objects To Diovan Link
Novartis has discontinued its unbranded direct-to-consumer advertising campaign on hypertension awareness following objections by FDA
Novartis Cleans Up Diovan Promotions
Company recalls 100,000 bottles of antibacterial soap that were distributed as a promotion for the antihypertensive.